Delivery Order SPE2DR25D2104-SPE2DR26F3RSG
Award Date 12/17/25
Potential Completion Date 12/18/25
Potential Value $1.2K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $67,559.94 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes. This non-competitive delivery order, issued on December 2, 2025, with an ultimate completion date of December 3, 2025, represents a firm fixed-price purchase of hepatitis B vaccine syringes to support federal medical supply needs. The award was fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. The order, valued at $4,710.99 with a completion date of September 10, 2025, represents a firm fixed price contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor that serves military and veteran...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 14, 2025, for HEPLISAV-B 20 MCG/0.5 ML syringes valued at $8,424.80 with a firm fixed price structure. This is a non-set-aside competitive award under an Indefinite Delivery Contract arrangement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 15, 2025. As a major pharmaceutical distributor and...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The order has a completion date of February 8, 2024 and a potential value of $1,577.28. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is not associated with any set-aside designation. Additionally, Amerisourcebergen Drug Corp holds...
- The Defense Logistics Agency awarded a $53,766.20 delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 ml syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,699.20 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award based on open competition. Performance will be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This delivery order is a child contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,637.55 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine approved for use in adults,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML vaccine syringes with a firm fixed price ceiling value of $5,476.12 and an ultimate completion date of August 25, 2025. This is a non-set-aside, competitively awarded delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $6,209.05 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes. The award, issued on December 17, 2025, with an ultimate completion date of December 18, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor supplying medical products to military and...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $3,154.56 to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999 and is in effect through December 2025. The...